Akiko Iwasaki
Director/Board Member at ROCHE HOLDING AG
Akiko Iwasaki active positions
Companies | Position | Start | End |
---|---|---|---|
ROCHE HOLDING AG | Director/Board Member | - | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Director/Board Member | - | - |
The American Association of Immunologists | Corporate Officer/Principal | 2017-12-31 | - |
Howard Hughes Medical Institute, Inc.
Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Corporate Officer/Principal | - | - |
Career history of Akiko Iwasaki
Former positions of Akiko Iwasaki
Companies | Position | Start | End |
---|---|---|---|
RIGImmune, Inc.
RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Founder | 2019-12-31 | - |
Xanadu Bio Inc. | Founder | 2020-12-31 | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Consultant / Advisor | 2020-12-17 | - |
Training of Akiko Iwasaki
University of Toronto | Undergraduate Degree |
Statistics
International
United States | 7 |
United Kingdom | 2 |
Canada | 2 |
Operational
Founder | 2 |
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Sectoral
Health Technology | 3 |
Finance | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ROCHE HOLDING AG | Health Technology |
Private companies | 6 |
---|---|
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Finance |
RIGImmune, Inc.
RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Commercial Services |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
The American Association of Immunologists | |
Howard Hughes Medical Institute, Inc.
Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Miscellaneous |
Xanadu Bio Inc. |
- Stock Market
- Insiders
- Akiko Iwasaki
- Experience